Seborrheic Keratosis

2
Pipeline Programs
1
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

DermBiont
DermBiontMA - Boston
2 programs
2
SM-020Phase 21 trial
SM-020 gel 1.0%Phase 21 trial
Active Trials
NCT05136144Unknown70Est. Jul 2024
NCT06108024Recruiting60Est. Oct 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
DermBiontSM-020 gel 1.0%
DermBiontSM-020

Clinical Trials (2)

Total enrollment: 130 patients across 2 trials

NCT06108024DermBiontSM-020 gel 1.0%

A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratosis

Start: Nov 2023Est. completion: Oct 202460 patients
Phase 2Recruiting

Adaptive Design Study for Safety and Efficacy of Treatment Regimens With SM-020 in Subjects With Seborrheic Keratosis

Start: Oct 2021Est. completion: Jul 202470 patients
Phase 2Unknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 130 patients
1 companies competing in this space